These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ý
|
Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
¨
|
Transition Report pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
|
|
|
|
|
|
Delaware
|
|
22-3240619
|
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
1111 Marcus Avenue
Lake Success, New York
|
|
11042
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
Large accelerated filer
|
ý
|
|
Accelerated filer
|
¨
|
|
|
|
|
|
|
|
|
|
|
|
Non-accelerated filer
(Do not check if a smaller reporting company)
|
¨
|
|
Smaller reporting company
|
¨
|
Emerging growth company
|
¨
|
|
|
Part I - Financial Information
|
Page
|
|
|
|
|
|
Item 1.
|
|
|
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
Item 2.
|
||
|
Item 3.
|
||
|
Item 4.
|
||
|
|
|
|
|
|
Part II - Other Information
|
|
|
|
|
|
|
Items 3 and 4 are not applicable
|
|
|
|
Item 1.
|
||
|
Item 1A.
|
||
|
Item 2.
|
||
|
Item 5.
|
||
|
Item 6.
|
||
|
|
|
|
|
|
||
|
|
||
|
|
December 31,
|
|
June 30,
|
||||
|
|
2017
|
|
2017
|
||||
|
ASSETS
|
(Unaudited)
|
|
|
||||
|
Current assets:
|
|
|
|
||||
|
Cash and cash equivalents
|
$
|
139,216
|
|
|
$
|
146,992
|
|
|
Accounts receivable, less allowance for doub
tful accounts of $1,201 and $1,
447, respectively
|
274,728
|
|
|
248,436
|
|
||
|
Inventories
|
502,372
|
|
|
427,308
|
|
||
|
Prepaid expenses and other current assets
|
62,994
|
|
|
52,045
|
|
||
|
Total current assets
|
979,310
|
|
|
874,781
|
|
||
|
Property, plant and equipment, net
|
386,077
|
|
|
370,511
|
|
||
|
Goodwill
|
1,083,696
|
|
|
1,059,981
|
|
||
|
Trademarks and other intangible assets, net
|
583,911
|
|
|
573,268
|
|
||
|
Investments and joint ventures
|
19,301
|
|
|
18,998
|
|
||
|
Other assets
|
35,042
|
|
|
33,565
|
|
||
|
Total assets
|
$
|
3,087,337
|
|
|
$
|
2,931,104
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
||||
|
Current liabilities:
|
|
|
|
||||
|
Accounts payable
|
$
|
263,395
|
|
|
$
|
222,136
|
|
|
Accrued expenses and other current liabilities
|
112,677
|
|
|
108,514
|
|
||
|
Current portion of long-term debt
|
25,021
|
|
|
9,844
|
|
||
|
Total current liabilities
|
401,093
|
|
|
340,494
|
|
||
|
Long-term debt, less current portion
|
742,125
|
|
|
740,304
|
|
||
|
Deferred income taxes
|
98,127
|
|
|
121,475
|
|
||
|
Other noncurrent liabilities
|
23,446
|
|
|
15,999
|
|
||
|
Total liabilities
|
1,264,791
|
|
|
1,218,272
|
|
||
|
Commitments and contingencies (Note 14)
|
|
|
|
||||
|
Stockholders’ equity:
|
|
|
|
||||
|
Preferred stock - $.01 par value, authorized 5,000 shares; issued and outstanding: none
|
—
|
|
|
—
|
|
||
|
Common stock - $.01 par value, authorized 150,000 shares; issued: 108,371 and 107,989 shares, respectively; outstanding: 103,918 and 103,702 shares, respectively
|
1,084
|
|
|
1,080
|
|
||
|
Additional paid-in capital
|
1,145,042
|
|
|
1,137,724
|
|
||
|
Retained earnings
|
935,771
|
|
|
868,822
|
|
||
|
Accumulated other comprehensive loss
|
(153,351
|
)
|
|
(195,479
|
)
|
||
|
|
1,928,546
|
|
|
1,812,147
|
|
||
|
Less: Treasury stock, at cos
t, 4,453 a
nd 4,287 shares, respectively
|
(106,000
|
)
|
|
(99,315
|
)
|
||
|
Total stockholders’ equity
|
1,822,546
|
|
|
1,712,832
|
|
||
|
Total liabilities and stockholders’ equity
|
$
|
3,087,337
|
|
|
$
|
2,931,104
|
|
|
|
Three Months Ended December 31,
|
|
Six Months Ended December 31,
|
||||||||||||
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
|
Net sales
|
$
|
775,204
|
|
|
$
|
739,999
|
|
|
$
|
1,483,480
|
|
|
$
|
1,421,463
|
|
|
Cost of sales
|
630,933
|
|
|
601,606
|
|
|
1,207,606
|
|
|
1,173,203
|
|
||||
|
Gross profit
|
144,271
|
|
|
138,393
|
|
|
275,874
|
|
|
248,260
|
|
||||
|
Selling, general and administrative expenses
|
90,372
|
|
|
85,187
|
|
|
181,093
|
|
|
170,154
|
|
||||
|
Amortization of acquired intangibles
|
4,909
|
|
|
4,693
|
|
|
9,820
|
|
|
9,421
|
|
||||
|
Acquisition related expenses, restructuring and integration charges
|
4,797
|
|
|
108
|
|
|
10,643
|
|
|
568
|
|
||||
|
Accounting review and remediation costs, net of insurance proceeds
|
4,451
|
|
|
7,005
|
|
|
3,093
|
|
|
12,966
|
|
||||
|
Long-lived asset impairment
|
3,449
|
|
|
—
|
|
|
3,449
|
|
|
—
|
|
||||
|
Operating income
|
36,293
|
|
|
41,400
|
|
|
67,776
|
|
|
55,151
|
|
||||
|
Interest and other financing expense, net
|
6,513
|
|
|
5,097
|
|
|
12,828
|
|
|
10,178
|
|
||||
|
Other (income)/expense, net
|
(760
|
)
|
|
(1,353
|
)
|
|
(3,897
|
)
|
|
(1,865
|
)
|
||||
|
Income before income taxes and equity in net income of equity-method investees
|
30,540
|
|
|
37,656
|
|
|
58,845
|
|
|
46,838
|
|
||||
|
(Benefit)/provision for income taxes
|
(16,369
|
)
|
|
10,509
|
|
|
(7,899
|
)
|
|
11,271
|
|
||||
|
Equity in net income of equity-method investees
|
(194
|
)
|
|
(38
|
)
|
|
(205
|
)
|
|
(222
|
)
|
||||
|
Net income
|
$
|
47,103
|
|
|
$
|
27,185
|
|
|
$
|
66,949
|
|
|
$
|
35,789
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Net income per common share:
|
|
|
|
|
|
|
|
||||||||
|
Basic
|
$
|
0.45
|
|
|
$
|
0.26
|
|
|
$
|
0.65
|
|
|
$
|
0.35
|
|
|
Diluted
|
$
|
0.45
|
|
|
$
|
0.26
|
|
|
$
|
0.64
|
|
|
$
|
0.34
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Shares used in the calculation of net income per common share:
|
|
|
|
|
|
|
|
||||||||
|
Basic
|
103,837
|
|
|
103,597
|
|
|
103,773
|
|
|
103,532
|
|
||||
|
Diluted
|
104,440
|
|
|
104,204
|
|
|
104,379
|
|
|
104,225
|
|
||||
|
|
Three Months Ended
|
||||||||||||||||||||||
|
|
December 31, 2017
|
|
December 31, 2016
|
||||||||||||||||||||
|
|
Pre-tax
amount
|
|
Tax (expense) benefit
|
|
After-tax amount
|
|
Pre-tax
amount
|
|
Tax benefit
|
|
After-tax amount
|
||||||||||||
|
Net income
|
|
|
|
|
$
|
47,103
|
|
|
|
|
|
|
$
|
27,185
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Other comprehensive income (loss):
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Foreign currency translation adjustments
|
$
|
8,336
|
|
|
$
|
—
|
|
|
8,336
|
|
|
$
|
(51,222
|
)
|
|
$
|
—
|
|
|
(51,222
|
)
|
||
|
Change in deferred gains (losses) on cash flow hedging instruments
|
—
|
|
|
—
|
|
|
—
|
|
|
(13
|
)
|
|
3
|
|
|
(10
|
)
|
||||||
|
Change in unrealized gain (loss) on available for sale investment
|
8
|
|
|
(3
|
)
|
|
5
|
|
|
(32
|
)
|
|
13
|
|
|
(19
|
)
|
||||||
|
Total other comprehensive income (loss)
|
$
|
8,344
|
|
|
$
|
(3
|
)
|
|
$
|
8,341
|
|
|
$
|
(51,267
|
)
|
|
$
|
16
|
|
|
$
|
(51,251
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Total comprehensive income (loss)
|
|
|
|
|
$
|
55,444
|
|
|
|
|
|
|
$
|
(24,066
|
)
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
|
Six Months Ended
|
||||||||||||||||||||||
|
|
December 31, 2017
|
|
December 31, 2016
|
||||||||||||||||||||
|
|
Pre-tax
amount
|
|
Tax (expense) benefit
|
|
After-tax amount
|
|
Pre-tax
amount
|
|
Tax benefit
|
|
After-tax amount
|
||||||||||||
|
Net income
|
|
|
|
|
$
|
66,949
|
|
|
|
|
|
|
$
|
35,789
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Other comprehensive income (loss):
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Foreign currency translation adjustments
|
$
|
42,197
|
|
|
$
|
—
|
|
|
42,197
|
|
|
$
|
(82,958
|
)
|
|
$
|
—
|
|
|
(82,958
|
)
|
||
|
Change in deferred gains (losses) on cash flow hedging instruments
|
(82
|
)
|
|
15
|
|
|
(67
|
)
|
|
(443
|
)
|
|
38
|
|
|
(405
|
)
|
||||||
|
Change in unrealized gain (loss) on available for sale investment
|
(2
|
)
|
|
—
|
|
|
(2
|
)
|
|
(89
|
)
|
|
30
|
|
|
(59
|
)
|
||||||
|
Total other comprehensive income (loss)
|
$
|
42,113
|
|
|
$
|
15
|
|
|
$
|
42,128
|
|
|
$
|
(83,490
|
)
|
|
$
|
68
|
|
|
$
|
(83,422
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Total comprehensive income (loss)
|
|
|
|
|
$
|
109,077
|
|
|
|
|
|
|
$
|
(47,633
|
)
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
|
Common Stock
|
|
Additional
|
|
|
|
|
|
|
|
Accumulated
Other
|
|
|
||||||||||||||||
|
|
|
|
Amount
|
|
Paid-in
|
|
Retained
|
|
Treasury Stock
|
|
Comprehensive
|
|
|
||||||||||||||||
|
|
Shares
|
|
at $.01
|
|
Capital
|
|
Earnings
|
|
Shares
|
|
Amount
|
|
Income (Loss)
|
|
Total
|
||||||||||||||
|
Balance at June 30, 2017
|
107,989
|
|
|
$
|
1,080
|
|
|
$
|
1,137,724
|
|
|
$
|
868,822
|
|
|
4,287
|
|
|
$
|
(99,315
|
)
|
|
$
|
(195,479
|
)
|
|
$
|
1,712,832
|
|
|
Net income
|
|
|
|
|
|
|
66,949
|
|
|
|
|
|
|
|
|
66,949
|
|
||||||||||||
|
Other comprehensive income (loss)
|
|
|
|
|
|
|
|
|
|
|
|
|
42,128
|
|
|
42,128
|
|
||||||||||||
|
Issuance of common stock pursuant to stock-based compensation plans
|
382
|
|
|
4
|
|
|
(4
|
)
|
|
|
|
|
|
|
|
|
|
—
|
|
||||||||||
|
Shares withheld for payment of employee payroll taxes due on shares issued under stock-based compensation plans
|
|
|
|
|
|
|
|
|
166
|
|
|
(6,685
|
)
|
|
|
|
(6,685
|
)
|
|||||||||||
|
Stock-based compensation expense
|
|
|
|
|
7,322
|
|
|
|
|
|
|
|
|
|
|
7,322
|
|
||||||||||||
|
Balance at December 31, 2017
|
108,371
|
|
|
$
|
1,084
|
|
|
$
|
1,145,042
|
|
|
$
|
935,771
|
|
|
4,453
|
|
|
$
|
(106,000
|
)
|
|
$
|
(153,351
|
)
|
|
$
|
1,822,546
|
|
|
|
Six Months Ended December 31,
|
||||||
|
|
2017
|
|
2016
|
||||
|
CASH FLOWS FROM OPERATING ACTIVITIES
|
|
|
|
||||
|
Net income
|
$
|
66,949
|
|
|
$
|
35,789
|
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
||||
|
Depreciation and amortization
|
34,972
|
|
|
34,168
|
|
||
|
Deferred income taxes
|
(28,808
|
)
|
|
(5,300
|
)
|
||
|
Equity in net income of equity-method investees
|
(205
|
)
|
|
(222
|
)
|
||
|
Stock based compensation
|
7,322
|
|
|
5,235
|
|
||
|
Impairment of long-lived assets
|
3,449
|
|
|
—
|
|
||
|
Other non-cash items, net
|
(1,716
|
)
|
|
130
|
|
||
|
Increase (decrease) in cash attributable to changes in operating assets and liabilities, net of amounts applicable to acquisitions:
|
|
|
|
||||
|
Accounts receivable
|
(19,194
|
)
|
|
15,885
|
|
||
|
Inventories
|
(65,431
|
)
|
|
(31,921
|
)
|
||
|
Other current assets
|
(4,521
|
)
|
|
20,854
|
|
||
|
Other assets and liabilities
|
4,636
|
|
|
(1,038
|
)
|
||
|
Accounts payable and accrued expenses
|
27,973
|
|
|
42,547
|
|
||
|
Net cash provided by operating activities
|
25,426
|
|
|
116,127
|
|
||
|
|
|
|
|
||||
|
CASH FLOWS FROM INVESTING ACTIVITIES
|
|
|
|
||||
|
Acquisitions of businesses, net of cash acquired
|
(13,064
|
)
|
|
—
|
|
||
|
Purchases of property and equipment
|
(31,027
|
)
|
|
(28,725
|
)
|
||
|
Proceeds from sale of business
|
—
|
|
|
5,419
|
|
||
|
Other
|
—
|
|
|
1,000
|
|
||
|
Net cash used in investing activities
|
(44,091
|
)
|
|
(22,306
|
)
|
||
|
|
|
|
|
||||
|
CASH FLOWS FROM FINANCING ACTIVITIES
|
|
|
|
||||
|
Borrowings under bank revolving credit facility
|
35,000
|
|
|
22,000
|
|
||
|
Repayments under bank revolving credit facility
|
(35,000
|
)
|
|
(56,500
|
)
|
||
|
Borrowings (repayments) of other debt, net
|
13,809
|
|
|
(13,690
|
)
|
||
|
Acquisition related contingent consideration
|
—
|
|
|
(2,498
|
)
|
||
|
Shares withheld for payment of employee payroll taxes
|
(6,685
|
)
|
|
(7,934
|
)
|
||
|
Net cash provided by (used in) financing activities
|
7,124
|
|
|
(58,622
|
)
|
||
|
|
|
|
|
||||
|
Effect of exchange rate changes on cash
|
3,765
|
|
|
(6,000
|
)
|
||
|
|
|
|
|
||||
|
Net (decrease) increase in cash and cash equivalents
|
(7,776
|
)
|
|
29,199
|
|
||
|
Cash and cash equivalents at beginning of period
|
146,992
|
|
|
127,926
|
|
||
|
Cash and cash equivalents at end of period
|
$
|
139,216
|
|
|
$
|
157,125
|
|
|
•
|
As required, we prospectively recognized discrete tax benefits of
$237
and
$836
, respectively, in the income tax line item of our consolidated income statement for the
three and six months ended
December 31, 2017
related to excess tax benefits upon vesting or settlement in that period.
|
|
•
|
We elected to adopt the cash flow presentation of the excess tax benefits retrospectively. As a result, we decreased our cash used in financing activities by
$3,314
for the
six months ended
December 31, 2016
.
|
|
•
|
We have elected to continue to estimate the number of stock-based awards expected to vest, rather than electing to account for forfeitures as they occur to determine the amount of compensation costs to be recognized in each period.
|
|
•
|
We have not changed our policy on statutory withholding requirements and will continue to allow an employee to withhold at the minimum statutory withholding requirements. Amounts paid by us to taxing authorities when directly withholding shares associated with employees’ income tax withholding obligations are classified as a financing activity in our cash flow statement.
|
|
•
|
We excluded the excess tax benefits from the assumed proceeds available to repurchase shares in the computation of our diluted earnings per share for the
three and six months ended
December 31, 2017
.
|
|
•
|
We did not have any material excess tax benefits previously recognized in additional paid-in capital; therefore, it was not necessary to record a deferred tax asset for the unrecognized tax benefits with an adjustment to opening retained earnings.
|
|
|
Three Months Ended December 31,
|
|
Six Months Ended December 31,
|
||||||||||||
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
|
Numerator:
|
|
|
|
|
|
|
|
||||||||
|
Net income
|
$
|
47,103
|
|
|
$
|
27,185
|
|
|
$
|
66,949
|
|
|
$
|
35,789
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Denominator:
|
|
|
|
|
|
|
|
||||||||
|
Basic weighted average shares outstanding
|
103,837
|
|
|
103,597
|
|
|
103,773
|
|
|
103,532
|
|
||||
|
Effect of dilutive stock options, unvested restricted stock and unvested restricted share units
|
603
|
|
|
607
|
|
|
606
|
|
|
693
|
|
||||
|
Diluted weighted average shares outstanding
|
104,440
|
|
|
104,204
|
|
|
104,379
|
|
|
104,225
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
|
Net income per common share:
|
|
|
|
|
|
|
|
||||||||
|
Basic
|
$
|
0.45
|
|
|
$
|
0.26
|
|
|
$
|
0.65
|
|
|
$
|
0.35
|
|
|
Diluted
|
$
|
0.45
|
|
|
$
|
0.26
|
|
|
$
|
0.64
|
|
|
$
|
0.34
|
|
|
|
December 31,
2017 |
|
June 30,
2017 |
||||
|
Finished goods
|
$
|
295,927
|
|
|
$
|
264,148
|
|
|
Raw materials, work-in-progress and packaging
|
206,445
|
|
|
163,160
|
|
||
|
|
$
|
502,372
|
|
|
$
|
427,308
|
|
|
|
December 31,
2017 |
|
June 30,
2017 |
||||
|
Land
|
$
|
34,713
|
|
|
$
|
33,930
|
|
|
Buildings and improvements
|
113,672
|
|
|
116,723
|
|
||
|
Machinery and equipment
|
367,366
|
|
|
350,689
|
|
||
|
Computer hardware and software
|
53,302
|
|
|
51,486
|
|
||
|
Furniture and fixtures
|
18,067
|
|
|
15,993
|
|
||
|
Leasehold improvements
|
30,290
|
|
|
29,296
|
|
||
|
Construction in progress
|
32,059
|
|
|
16,119
|
|
||
|
|
649,469
|
|
|
614,236
|
|
||
|
Less: Accumulated depreciation and amortization
|
263,392
|
|
|
243,725
|
|
||
|
|
$
|
386,077
|
|
|
$
|
370,511
|
|
|
|
United States
|
|
United Kingdom
|
|
Hain Pure Protein
|
|
Rest of World
|
|
Total
|
||||||||||
|
Balance as of June 30, 2017 (a)
|
$
|
591,416
|
|
|
$
|
329,135
|
|
|
$
|
41,089
|
|
|
$
|
98,341
|
|
|
$
|
1,059,981
|
|
|
Acquisition activity
|
—
|
|
|
6,936
|
|
|
—
|
|
|
—
|
|
|
6,936
|
|
|||||
|
Reallocation of goodwill between reporting units (b)
|
(35,519
|
)
|
|
35,519
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
|
Translation and other adjustments, net
|
134
|
|
|
13,567
|
|
|
—
|
|
|
3,078
|
|
|
16,779
|
|
|||||
|
Balance as of December 31, 2017 (a)
|
$
|
556,031
|
|
|
$
|
385,157
|
|
|
$
|
41,089
|
|
|
$
|
101,419
|
|
|
$
|
1,083,696
|
|
|
|
December 31,
2017 |
|
June 30,
2017 |
||||
|
Non-amortized intangible assets:
|
|
|
|
||||
|
Trademarks and tradenames (a)
|
$
|
436,106
|
|
|
$
|
424,817
|
|
|
Amortized intangible assets:
|
|
|
|
||||
|
Other intangibles
|
259,343
|
|
|
247,712
|
|
||
|
Less: accumulated amortization
|
(111,538
|
)
|
|
(99,261
|
)
|
||
|
Net carrying amount
|
$
|
583,911
|
|
|
$
|
573,268
|
|
|
|
Three Months Ended December 31,
|
|
Six Months Ended December 31,
|
||||||||||||
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
|
Amortization of acquired intangibles
|
$
|
4,909
|
|
|
$
|
4,693
|
|
|
$
|
9,820
|
|
|
$
|
9,421
|
|
|
|
December 31,
2017 |
|
June 30,
2017 |
||||
|
Credit Agreement borrowings payable to banks
|
$
|
735,088
|
|
|
$
|
733,715
|
|
|
Tilda short-term borrowing arrangements
|
19,094
|
|
|
7,761
|
|
||
|
Other borrowings
|
12,964
|
|
|
8,672
|
|
||
|
|
767,146
|
|
|
750,148
|
|
||
|
Short-term borrowings and current portion of long-term debt
|
25,021
|
|
|
9,844
|
|
||
|
Long-term debt, less current portion
|
$
|
742,125
|
|
|
$
|
740,304
|
|
|
|
Three Months Ended December 31,
|
|
Six Months Ended December 31,
|
||||||||||||
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
|
Foreign currency translation adjustments:
|
|
|
|
|
|
|
|
||||||||
|
Other comprehensive income (loss) before reclassifications
(1)
|
$
|
8,336
|
|
|
$
|
(51,222
|
)
|
|
$
|
42,197
|
|
|
$
|
(82,958
|
)
|
|
Deferred gain
s/(losses)
on cash flow hedging instruments:
|
|
|
|
|
|
|
|
||||||||
|
Other comprehensive income before reclassifications
|
—
|
|
|
45
|
|
|
39
|
|
|
101
|
|
||||
|
Amounts reclassified into income
(2)
|
—
|
|
|
(55
|
)
|
|
(106
|
)
|
|
(506
|
)
|
||||
|
Unrealized gain/(loss) on available for sale investment:
|
|
|
|
|
|
|
|
||||||||
|
Other comprehensive loss before reclassifications
|
5
|
|
|
(19
|
)
|
|
(2
|
)
|
|
(69
|
)
|
||||
|
Amounts reclassified into income
(3)
|
—
|
|
|
—
|
|
|
—
|
|
|
10
|
|
||||
|
Net change in accumulated other comprehensive income (loss)
|
$
|
8,341
|
|
|
$
|
(51,251
|
)
|
|
$
|
42,128
|
|
|
$
|
(83,422
|
)
|
|
(1)
|
Foreign currency translation adjustments included intra-entity foreign currency transactions that were of a long-term investment nature and were a gain of
$315
and a loss of
$12,908
for the
three months ended
December 31, 2017
and
2016
,
respectively, and a gain of
$1,066
and a loss of
$20,061
for the
six months ended
December 31, 2017
and
2016
, respectively.
|
|
(2)
|
Amounts reclassified into income for deferred gains/(losses) on cash flow hedging instruments are recorded in “Cost of sales” in the Consolidated Statements of Income and, before taxes, were
$530
for the
three months ended
December 31, 2016
and
$132
and
$1,150
for the
six months ended
December 31, 2017
and
2016
, respectively. There were
no
amounts reclassified into income for deferred gains/(losses) on cash flow hedging instruments for the
three months ended
December 31, 2017
.
|
|
(3)
|
Amounts reclassified into income for losses on sale of available for sale investments were based on the average cost of the shares held (See Note 12, Investments and Joint Ventures). Such amounts are recorded in “Other (income)/expense, net” in the Consolidated Statements of Income and were
$16
before taxes for the
six months ended
December 31, 2016
. There were
no
amounts reclassified into income for losses on sale of available for sale investments for the
three and six months ended
December 31, 2017
.
|
|
|
Three Months Ended December 31,
|
|
Six Months Ended December 31,
|
||||||||||||
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
|
Compensation cost (included in selling, general and administrative expense)
|
$
|
4,158
|
|
|
$
|
2,531
|
|
|
$
|
7,322
|
|
|
$
|
5,235
|
|
|
Related income tax benefit
|
$
|
1,187
|
|
|
$
|
949
|
|
|
$
|
2,421
|
|
|
$
|
1,963
|
|
|
|
Number of Options
|
|
Weighted
Average
Exercise
Price
|
|
Weighted
Average
Contractual
Life (years)
|
|
Aggregate
Intrinsic Value
|
|||||
|
Options outstanding and exercisable at June 30, 2017
|
122
|
|
|
$
|
2.26
|
|
|
|
|
|
||
|
Exercised
|
—
|
|
|
$
|
—
|
|
|
|
|
|
||
|
Options outstanding and exercisable at December 31, 2017
|
122
|
|
|
$
|
2.26
|
|
|
13.5
|
|
$
|
4,893
|
|
|
|
Six Months Ended December 31,
|
||||
|
|
2017
|
|
2016
|
||
|
Intrinsic value of options exercised
|
—
|
|
|
6,507
|
|
|
Tax benefit recognized from stock option exercises
|
—
|
|
|
2,538
|
|
|
|
Number of Shares
and Units
|
|
Weighted
Average Grant
Date Fair
Value (per share)
|
|||
|
Non-vested restricted stock, restricted share units, and performance units at June 30, 2017
|
992
|
|
|
$
|
27.59
|
|
|
Granted
|
431
|
|
|
$
|
33.85
|
|
|
Vested
|
(382
|
)
|
|
$
|
36.96
|
|
|
Forfeited
|
(14
|
)
|
|
$
|
29.59
|
|
|
Non-vested restricted stock, restricted share units, and performance units at December 31, 2017
|
1,027
|
|
|
$
|
26.71
|
|
|
|
Six Months Ended December 31,
|
||||||
|
|
2017
|
|
2016
|
||||
|
Fair value of restricted stock and restricted share units granted
|
$
|
14,595
|
|
|
$
|
—
|
|
|
Fair value of shares vested
|
$
|
14,238
|
|
|
$
|
9,004
|
|
|
Tax benefit recognized from restricted shares vesting
|
$
|
4,887
|
|
|
$
|
3,464
|
|
|
•
|
Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
|
|
•
|
Level 2 – Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and
|
|
•
|
Level 3 – Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
|
|
|
Total
|
|
Quoted
prices in
active
markets
(Level 1)
|
|
Significant
other
observable
inputs
(Level 2)
|
|
Significant
unobservable
inputs
(Level 3)
|
||||||||
|
Assets:
|
|
|
|
|
|
|
|
||||||||
|
Cash equivalents
|
$
|
20,813
|
|
|
$
|
20,813
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Forward foreign currency contracts
|
39
|
|
|
—
|
|
|
39
|
|
|
—
|
|
||||
|
Available for sale securities
|
880
|
|
|
880
|
|
|
—
|
|
|
—
|
|
||||
|
Total
|
$
|
21,732
|
|
|
$
|
21,693
|
|
|
$
|
39
|
|
|
$
|
—
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
||||||||
|
Forward foreign currency contracts
|
$
|
216
|
|
|
$
|
—
|
|
|
$
|
216
|
|
|
$
|
—
|
|
|
Contingent consideration, non-current
|
4,559
|
|
|
—
|
|
|
—
|
|
|
4,559
|
|
||||
|
Total
|
$
|
4,775
|
|
|
$
|
—
|
|
|
$
|
216
|
|
|
$
|
4,559
|
|
|
|
Total
|
|
Quoted
prices in
active
markets
(Level 1)
|
|
Significant
other
observable
inputs
(Level 2)
|
|
Significant
unobservable
inputs
(Level 3)
|
||||||||
|
Assets:
|
|
|
|
|
|
|
|
||||||||
|
Cash equivalents
|
$
|
21,800
|
|
|
$
|
21,800
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Forward foreign currency contracts
|
99
|
|
|
—
|
|
|
99
|
|
|
—
|
|
||||
|
Available for sale securities
|
882
|
|
|
882
|
|
|
—
|
|
|
—
|
|
||||
|
Total
|
$
|
22,781
|
|
|
$
|
22,682
|
|
|
$
|
99
|
|
|
$
|
—
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
||||||||
|
Forward foreign currency contracts
|
$
|
53
|
|
|
$
|
—
|
|
|
$
|
53
|
|
|
$
|
—
|
|
|
Contingent consideration, non-current
|
2,656
|
|
|
—
|
|
|
—
|
|
|
2,656
|
|
||||
|
Total
|
$
|
2,709
|
|
|
$
|
—
|
|
|
$
|
53
|
|
|
$
|
2,656
|
|
|
Balance as of June 30, 2017
|
$
|
2,656
|
|
|
Fair value of initial contingent consideration
(a)
|
1,547
|
|
|
|
Contingent consideration adjustment
(b)
|
325
|
|
|
|
Translation adjustment
|
31
|
|
|
|
Balance as of December 31, 2017
|
$
|
4,559
|
|
|
|
Three Months Ended December 31,
|
|
Six Months Ended December 31,
|
||||||||||||
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
|
Net Sales:
|
|
|
|
|
|
|
|
||||||||
|
United States
|
$
|
270,303
|
|
|
$
|
278,640
|
|
|
$
|
533,962
|
|
|
$
|
532,872
|
|
|
United Kingdom
|
238,201
|
|
|
212,312
|
|
|
460,646
|
|
|
432,463
|
|
||||
|
Hain Pure Protein
|
158,972
|
|
|
152,979
|
|
|
278,029
|
|
|
269,648
|
|
||||
|
Rest of World
|
107,728
|
|
|
96,068
|
|
|
210,843
|
|
|
186,480
|
|
||||
|
|
$
|
775,204
|
|
|
$
|
739,999
|
|
|
$
|
1,483,480
|
|
|
$
|
1,421,463
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Operating Income:
|
|
|
|
|
|
|
|
||||||||
|
United States
|
$
|
21,861
|
|
|
$
|
39,928
|
|
|
$
|
42,722
|
|
|
$
|
58,722
|
|
|
United Kingdom
|
13,598
|
|
|
9,321
|
|
|
23,199
|
|
|
17,140
|
|
||||
|
Hain Pure Protein
|
5,328
|
|
|
3,541
|
|
|
7,570
|
|
|
2,523
|
|
||||
|
Rest of World
|
10,535
|
|
|
7,477
|
|
|
19,532
|
|
|
12,532
|
|
||||
|
|
$
|
51,322
|
|
|
$
|
60,267
|
|
|
$
|
93,023
|
|
|
$
|
90,917
|
|
|
Corporate and Other
(a)
|
(15,029
|
)
|
|
(18,867
|
)
|
|
(25,247
|
)
|
|
(35,766
|
)
|
||||
|
|
$
|
36,293
|
|
|
$
|
41,400
|
|
|
$
|
67,776
|
|
|
$
|
55,151
|
|
|
|
December 31,
2017 |
|
June 30,
2017 |
||||
|
United States
|
$
|
187,960
|
|
|
$
|
194,348
|
|
|
United Kingdom
|
173,299
|
|
|
165,396
|
|
||
|
All Other
|
79,161
|
|
|
63,330
|
|
||
|
Total
|
$
|
440,420
|
|
|
$
|
423,074
|
|
|
|
Three Months Ended December 31,
|
|
Six Months Ended December 31,
|
||||||||||||
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
|
United States
|
$
|
445,031
|
|
|
$
|
446,412
|
|
|
$
|
842,382
|
|
|
$
|
832,180
|
|
|
United Kingdom
|
238,201
|
|
|
212,312
|
|
|
460,646
|
|
|
432,463
|
|
||||
|
All Other
|
91,972
|
|
|
81,275
|
|
|
180,452
|
|
|
156,820
|
|
||||
|
Total
|
$
|
775,204
|
|
|
$
|
739,999
|
|
|
$
|
1,483,480
|
|
|
$
|
1,421,463
|
|
|
|
Three Months Ended
|
|
Change in
|
||||||||||||||
|
|
December 31, 2017
|
|
December 31, 2016
|
|
Dollars
|
|
Percentage
|
||||||||||
|
Net sales
|
$
|
775,204
|
|
|
100.0%
|
|
$
|
739,999
|
|
|
100.0%
|
|
$
|
35,205
|
|
|
4.8%
|
|
Cost of sales
|
630,933
|
|
|
81.4%
|
|
601,606
|
|
|
81.3%
|
|
29,327
|
|
|
4.9%
|
|||
|
Gross profit
|
144,271
|
|
|
18.6%
|
|
138,393
|
|
|
18.7%
|
|
5,878
|
|
|
4.2%
|
|||
|
Selling, general and administrative expenses
|
90,372
|
|
|
11.7%
|
|
85,187
|
|
|
11.5%
|
|
5,185
|
|
|
6.1%
|
|||
|
Amortization of acquired intangibles
|
4,909
|
|
|
0.6%
|
|
4,693
|
|
|
0.6%
|
|
216
|
|
|
4.6%
|
|||
|
Acquisition related expenses, restructuring and integration charges
|
4,797
|
|
|
0.6%
|
|
108
|
|
|
—
|
|
4,689
|
|
|
*
|
|||
|
Accounting review and remediation costs, net of insurance proceeds
|
4,451
|
|
|
0.6%
|
|
7,005
|
|
|
0.9%
|
|
(2,554
|
)
|
|
(36.5)%
|
|||
|
Long-lived asset impairment
|
3,449
|
|
|
0.4%
|
|
—
|
|
|
—
|
|
3,449
|
|
|
100.0%
|
|||
|
Operating income
|
36,293
|
|
|
4.7%
|
|
41,400
|
|
|
5.6%
|
|
(5,107
|
)
|
|
(12.3)%
|
|||
|
Interest and other financing expense, net
|
6,513
|
|
|
0.8%
|
|
5,097
|
|
|
0.7%
|
|
1,416
|
|
|
27.8%
|
|||
|
Other (income)/expense, net
|
(760
|
)
|
|
(0.1)%
|
|
(1,353
|
)
|
|
(0.2)%
|
|
593
|
|
|
43.8%
|
|||
|
Income before income taxes and equity in net income of equity-method investees
|
30,540
|
|
|
3.9%
|
|
37,656
|
|
|
5.1%
|
|
(7,116
|
)
|
|
(18.9)%
|
|||
|
(Benefit)/provision for income taxes
|
(16,369
|
)
|
|
(2.1)%
|
|
10,509
|
|
|
1.4%
|
|
(26,878
|
)
|
|
*
|
|||
|
Equity in net income of equity-method investees
|
(194
|
)
|
|
—
|
|
(38
|
)
|
|
—
|
|
(156
|
)
|
|
*
|
|||
|
Net income
|
$
|
47,103
|
|
|
6.1%
|
|
$
|
27,185
|
|
|
3.7%
|
|
$
|
19,918
|
|
|
73.3%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Adjusted EBITDA
|
$
|
82,678
|
|
|
10.7%
|
|
$
|
69,498
|
|
|
9.4%
|
|
$
|
13,180
|
|
|
19.0%
|
|
(dollars in thousands)
|
|
United States
|
|
United Kingdom
|
|
Hain Pure Protein
|
|
Rest of World
|
|
Corporate and Other
|
|
Consolidated
|
||||||||||||
|
Net sales
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Three months ended 12/31/17
|
|
$
|
270,303
|
|
|
$
|
238,201
|
|
|
$
|
158,972
|
|
|
$
|
107,728
|
|
|
$
|
—
|
|
|
$
|
775,204
|
|
|
Three months ended 12/31/16
|
|
278,640
|
|
|
212,312
|
|
|
152,979
|
|
|
96,068
|
|
|
—
|
|
|
739,999
|
|
||||||
|
$ change
|
|
$
|
(8,337
|
)
|
|
$
|
25,889
|
|
|
$
|
5,993
|
|
|
$
|
11,660
|
|
|
n/a
|
|
|
$
|
35,205
|
|
|
|
% change
|
|
(3.0
|
)%
|
|
12.2
|
%
|
|
3.9
|
%
|
|
12.1
|
%
|
|
n/a
|
|
|
4.8
|
%
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Operating income (loss)
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Three months ended 12/31/17
|
|
$
|
21,861
|
|
|
$
|
13,598
|
|
|
$
|
5,328
|
|
|
$
|
10,535
|
|
|
$
|
(15,029
|
)
|
|
$
|
36,293
|
|
|
Three months ended 12/31/16
|
|
39,928
|
|
|
9,321
|
|
|
3,541
|
|
|
7,477
|
|
|
(18,867
|
)
|
|
41,400
|
|
||||||
|
$ change
|
|
$
|
(18,067
|
)
|
|
$
|
4,277
|
|
|
$
|
1,787
|
|
|
$
|
3,058
|
|
|
$
|
3,838
|
|
|
$
|
(5,107
|
)
|
|
% change
|
|
(45.2
|
)%
|
|
45.9
|
%
|
|
50.5
|
%
|
|
40.9
|
%
|
|
20.3
|
%
|
|
(12.3
|
)%
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Operating income margin
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Three months ended 12/31/17
|
|
8.1
|
%
|
|
5.7
|
%
|
|
3.4
|
%
|
|
9.8
|
%
|
|
n/a
|
|
|
4.7
|
%
|
||||||
|
Three months ended 12/31/16
|
|
14.3
|
%
|
|
4.4
|
%
|
|
2.3
|
%
|
|
7.8
|
%
|
|
n/a
|
|
|
5.6
|
%
|
||||||
|
|
Six Months Ended
|
|
Change in
|
||||||||||||||
|
|
December 31, 2017
|
|
December 31, 2016
|
|
Dollars
|
|
Percentage
|
||||||||||
|
Net sales
|
$
|
1,483,480
|
|
|
100.0%
|
|
$
|
1,421,463
|
|
|
100.0%
|
|
$
|
62,017
|
|
|
4.4%
|
|
Cost of sales
|
1,207,606
|
|
|
81.4%
|
|
1,173,203
|
|
|
82.5%
|
|
34,403
|
|
|
2.9%
|
|||
|
Gross profit
|
275,874
|
|
|
18.6%
|
|
248,260
|
|
|
17.5%
|
|
27,614
|
|
|
11.1%
|
|||
|
Selling, general and administrative expenses
|
181,093
|
|
|
12.2%
|
|
170,154
|
|
|
12.0%
|
|
10,939
|
|
|
6.4%
|
|||
|
Amortization of acquired intangibles
|
9,820
|
|
|
0.7%
|
|
9,421
|
|
|
0.7%
|
|
399
|
|
|
4.2%
|
|||
|
Acquisition related expenses, restructuring and integration charges
|
10,643
|
|
|
0.7%
|
|
568
|
|
|
—
|
|
10,075
|
|
|
*
|
|||
|
Accounting review and remediation costs, net of insurance proceeds
|
3,093
|
|
|
0.2%
|
|
12,966
|
|
|
0.9%
|
|
(9,873
|
)
|
|
(76.1)%
|
|||
|
Long-lived asset impairment
|
3,449
|
|
|
0.2%
|
|
—
|
|
|
—
|
|
3,449
|
|
|
100.0%
|
|||
|
Operating income
|
67,776
|
|
|
4.6%
|
|
55,151
|
|
|
3.9%
|
|
12,625
|
|
|
22.9%
|
|||
|
Interest and other financing expense, net
|
12,828
|
|
|
0.9%
|
|
10,178
|
|
|
0.7%
|
|
2,650
|
|
|
26.0%
|
|||
|
Other (income)/expense, net
|
(3,897
|
)
|
|
(0.3)%
|
|
(1,865
|
)
|
|
(0.1)%
|
|
(2,032
|
)
|
|
(109.0)%
|
|||
|
Income before income taxes and equity in net income of equity-method investees
|
58,845
|
|
|
4.0%
|
|
46,838
|
|
|
3.3%
|
|
12,007
|
|
|
25.6%
|
|||
|
(Benefit)/Provision for income taxes
|
(7,899
|
)
|
|
(0.5)%
|
|
11,271
|
|
|
0.8%
|
|
(19,170
|
)
|
|
*
|
|||
|
Equity in net income of equity-method investees
|
(205
|
)
|
|
—
|
|
(222
|
)
|
|
—
|
|
17
|
|
|
7.7%
|
|||
|
Net income
|
$
|
66,949
|
|
|
4.5%
|
|
$
|
35,789
|
|
|
2.5%
|
|
$
|
31,160
|
|
|
87.1%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Adjusted EBITDA
|
$
|
142,190
|
|
|
9.6%
|
|
$
|
115,116
|
|
|
8.1%
|
|
$
|
27,074
|
|
|
23.5%
|
|
(dollars in thousands)
|
|
United States
|
|
United Kingdom
|
|
Hain Pure Protein
|
|
Rest of World
|
|
Corporate and Other
|
|
Consolidated
|
||||||||||||
|
Net sales
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Six months ended 12/31/17
|
|
$
|
533,962
|
|
|
$
|
460,646
|
|
|
$
|
278,029
|
|
|
$
|
210,843
|
|
|
$
|
—
|
|
|
$
|
1,483,480
|
|
|
Six months ended 12/31/16
|
|
532,872
|
|
|
432,463
|
|
|
269,648
|
|
|
186,480
|
|
|
—
|
|
|
1,421,463
|
|
||||||
|
$ change
|
|
$
|
1,090
|
|
|
$
|
28,183
|
|
|
$
|
8,381
|
|
|
$
|
24,363
|
|
|
n/a
|
|
|
$
|
62,017
|
|
|
|
% change
|
|
0.2
|
%
|
|
6.5
|
%
|
|
3.1
|
%
|
|
13.1
|
%
|
|
n/a
|
|
|
4.4
|
%
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Operating income (loss)
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Six months ended 12/31/17
|
|
$
|
42,722
|
|
|
$
|
23,199
|
|
|
$
|
7,570
|
|
|
$
|
19,532
|
|
|
$
|
(25,247
|
)
|
|
$
|
67,776
|
|
|
Six months ended 12/31/16
|
|
58,722
|
|
|
17,140
|
|
|
2,523
|
|
|
12,532
|
|
|
(35,766
|
)
|
|
55,151
|
|
||||||
|
$ change
|
|
$
|
(16,000
|
)
|
|
$
|
6,059
|
|
|
$
|
5,047
|
|
|
$
|
7,000
|
|
|
$
|
10,519
|
|
|
$
|
12,625
|
|
|
% change
|
|
(27.2
|
)%
|
|
35.4
|
%
|
|
200.0
|
%
|
|
55.9
|
%
|
|
29.4
|
%
|
|
22.9
|
%
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Operating income margin
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Six months ended 12/31/17
|
|
8.0
|
%
|
|
5.0
|
%
|
|
2.7
|
%
|
|
9.3
|
%
|
|
n/a
|
|
|
4.6
|
%
|
||||||
|
Six months ended 12/31/16
|
|
11.0
|
%
|
|
4.0
|
%
|
|
0.9
|
%
|
|
6.7
|
%
|
|
n/a
|
|
|
3.9
|
%
|
||||||
|
|
Six Months Ended December 31,
|
|
Change in
|
|||||||||||
|
(amounts in thousands)
|
2017
|
|
2016
|
|
Dollars
|
|
Percentage
|
|||||||
|
Cash flows provided by (used in):
|
|
|
|
|
|
|
|
|||||||
|
Operating activities
|
$
|
25,426
|
|
|
$
|
116,127
|
|
|
$
|
(90,701
|
)
|
|
(78.1
|
)%
|
|
Investing activities
|
(44,091
|
)
|
|
(22,306
|
)
|
|
(21,785
|
)
|
|
(97.7
|
)%
|
|||
|
Financing activities
|
7,124
|
|
|
(58,622
|
)
|
|
65,746
|
|
|
112.2
|
%
|
|||
|
Effect of exchange rate changes on cash
|
3,765
|
|
|
(6,000
|
)
|
|
9,765
|
|
|
162.8
|
%
|
|||
|
Net (decrease) increase in cash
|
$
|
(7,776
|
)
|
|
$
|
29,199
|
|
|
$
|
(36,975
|
)
|
|
(126.6
|
)%
|
|
(amounts in thousands)
|
United Kingdom
|
|
Rest of World
|
|
Hain Consolidated
|
||||||
|
Net sales - Three months ended 12/31/2017
|
$
|
238,201
|
|
|
$
|
107,728
|
|
|
$
|
775,204
|
|
|
Impact of foreign currency exchange
|
(14,987
|
)
|
|
(6,161
|
)
|
|
(21,148
|
)
|
|||
|
Net sales on a constant currency basis - Three months ended 12/31/2017
|
$
|
223,214
|
|
|
$
|
101,567
|
|
|
$
|
754,056
|
|
|
|
|
|
|
|
|
||||||
|
Net sales - Three months ended 12/31/2016
|
$
|
212,312
|
|
|
$
|
96,068
|
|
|
$
|
739,999
|
|
|
Net sales growth on a constant currency
|
5.1
|
%
|
|
5.7
|
%
|
|
1.9
|
%
|
|||
|
|
|
|
|
|
|
||||||
|
Net sales - Six months ended 12/31/2017
|
$
|
460,646
|
|
|
$
|
210,843
|
|
|
$
|
1,483,480
|
|
|
Impact of foreign currency exchange
|
(14,954
|
)
|
|
(10,338
|
)
|
|
(25,292
|
)
|
|||
|
Net sales on a constant currency basis - Six months ended 12/31/2017
|
$
|
445,692
|
|
|
$
|
200,505
|
|
|
$
|
1,458,188
|
|
|
|
|
|
|
|
|
||||||
|
Net sales - Six months ended 12/31/2016
|
$
|
432,463
|
|
|
$
|
186,480
|
|
|
$
|
1,421,463
|
|
|
Net sales growth on a constant currency
|
3.1
|
%
|
|
7.5
|
%
|
|
2.6
|
%
|
|||
|
|
Three Months Ended December 31,
|
|
Six Months Ended December 31,
|
||||||||||||
|
(amounts in thousands)
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
|
Net income
|
$
|
47,103
|
|
|
$
|
27,185
|
|
|
$
|
66,949
|
|
|
$
|
35,789
|
|
|
(Benefit)/provision for income taxes
|
(16,369
|
)
|
|
10,509
|
|
|
(7,899
|
)
|
|
11,271
|
|
||||
|
Interest expense, net
|
5,827
|
|
|
4,426
|
|
|
11,447
|
|
|
8,780
|
|
||||
|
Depreciation and amortization
|
17,346
|
|
|
16,948
|
|
|
34,972
|
|
|
34,168
|
|
||||
|
Equity in net income of equity-method investees
|
(194
|
)
|
|
(38
|
)
|
|
(205
|
)
|
|
(222
|
)
|
||||
|
Stock-based compensation expense
|
4,158
|
|
|
2,531
|
|
|
7,322
|
|
|
5,235
|
|
||||
|
Long-lived asset impairment
|
3,449
|
|
|
—
|
|
|
3,449
|
|
|
—
|
|
||||
|
Unrealized currency gains
|
(287
|
)
|
|
(1,984
|
)
|
|
(3,706
|
)
|
|
(3,277
|
)
|
||||
|
EBITDA
|
61,033
|
|
|
59,577
|
|
|
112,329
|
|
|
91,744
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
|
Acquisition related expenses, restructuring and integration charges, and other
|
4,797
|
|
|
108
|
|
|
10,643
|
|
|
1,516
|
|
||||
|
Accounting review and remediation costs, net of insurance proceeds
|
4,451
|
|
|
7,005
|
|
|
3,093
|
|
|
12,966
|
|
||||
|
Losses on terminated chilled desserts contract
|
2,142
|
|
|
—
|
|
|
3,614
|
|
|
—
|
|
||||
|
U.K. and Hain Pure Protein start-up costs
|
2,381
|
|
|
—
|
|
|
3,464
|
|
|
—
|
|
||||
|
Discontinuation of Round Hill Brand
|
2,177
|
|
|
—
|
|
|
2,177
|
|
|
—
|
|
||||
|
Hain Pure Protein network distribution redesign
|
1,952
|
|
|
—
|
|
|
1,952
|
|
|
—
|
|
||||
|
Co-packer disruption
|
1,567
|
|
|
—
|
|
|
2,740
|
|
|
—
|
|
||||
|
Regulated packaging change
|
1,007
|
|
|
—
|
|
|
1,007
|
|
|
—
|
|
||||
|
Plant closure related costs
|
700
|
|
|
1,804
|
|
|
700
|
|
|
1,804
|
|
||||
|
Hain Pure Protein feed formulation test
|
471
|
|
|
—
|
|
|
471
|
|
|
—
|
|
||||
|
SKU rationalization
|
—
|
|
|
160
|
|
|
—
|
|
|
5,359
|
|
||||
|
U.K. deferred synergies due to CMA Board decision
|
—
|
|
|
447
|
|
|
—
|
|
|
918
|
|
||||
|
Recall and other related costs
|
—
|
|
|
397
|
|
|
—
|
|
|
809
|
|
||||
|
Adjusted EBITDA
|
$
|
82,678
|
|
|
$
|
69,498
|
|
|
$
|
142,190
|
|
|
$
|
115,116
|
|
|
|
Six Months Ended December 31,
|
||||||
|
(amounts in thousands)
|
2017
|
|
2016
|
||||
|
Cash flow provided by operating activities
|
$
|
25,426
|
|
|
$
|
116,127
|
|
|
Purchase of property, plant and equipment
|
(31,027
|
)
|
|
(28,725
|
)
|
||
|
Operating free cash flow
|
$
|
(5,601
|
)
|
|
$
|
87,402
|
|
|
Period
|
(a)
Total number
of shares
purchased (1)
|
|
(b)
Average
price paid
per share
|
|
(c)
Total number of
shares purchased
as part of
publicly
announced plans
|
|
(d)
Maximum
number of shares
that may yet be
purchased under
the plans (in millions of dollars) (2)
|
|||||
|
October 1, 2017 - October 31, 2017
|
22,444
|
|
|
$
|
37.06
|
|
|
—
|
|
|
250
|
|
|
November 1, 2017 - November 30, 2017
|
63,981
|
|
|
40.89
|
|
|
—
|
|
|
250
|
|
|
|
December 1, 2017 - December 31, 2017
|
27,814
|
|
|
40.98
|
|
|
—
|
|
|
250
|
|
|
|
Total
|
114,239
|
|
|
$
|
40.16
|
|
|
—
|
|
|
—
|
|
|
(1)
|
Shares surrendered for payment of employee payroll taxes due on shares issued under stockholder-approved stock-based compensation plans.
|
|
(2)
|
On June 21, 2017, the Company’s Board of Directors authorized the repurchase of up to $250 million of the Company’s issued and outstanding common stock. Repurchases may be made from time to time in the open market, pursuant to preset trading plans, in private transactions or otherwise. The authorization does not have a stated expiration date.
|
|
Exhibit
Number
|
|
Description
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
|
THE HAIN CELESTIAL GROUP, INC.
|
|
|
|
(Registrant)
|
|
|
|
|
|
Date:
|
February 7, 2018
|
/s/ Irwin D. Simon
|
|
|
|
Irwin D. Simon,
Chairman, President and Chief
Executive Officer
|
|
Date:
|
February 7, 2018
|
/s/ James Langrock
|
|
|
|
James Langrock,
Executive Vice President and
Chief Financial Officer
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|